Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04321031 · ClinicalTrials.gov registry record · Phase 2
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
A Phase 2 study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
- 20
- Study locations
NCT04321031 is a Phase 2 study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis that has completed, run by Pfizer. The registered enrollment target is 256 participants, above the 87-participant average among 9 other Nonalcoholic Fatty Liver Disease trials with a reported enrollment target (194% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT04321031, a Phase 2 study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06865571
- DRUG PF-05221304
Study Locations (20)
California
- Hope Clinical Research - Canoga Park
- Sharp Coronado Hospital - Coronado
- Southern California Research Center - Coronado
- Magnolia Surgery Center - El Cajon
- Encino Hospital Medical Center - Encino
- National Research Institute - Huntington Park
- Investigational Drug Service, Altman Clinical and Translational Research Institute (ACTRI) - La Jolla
- University of California San Diego, Altman Clinical and Translational Research Institute Clinic - La Jolla
- UCSD Altman Clinical and Transitional Research Institute - La Jolla
- A V Pediatrics, Allergy & Family Medicine - Lancaster
- Jatinder S. Pruthi, M.D. FACG CPI - Lancaster
- Om Research LLC - Lancaster
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars-Sinai Advanced Health Sciences Pavilion (Imaging) - Los Angeles
Arizona
- Institute for Liver Health dba Arizona Liver Health - Chandler
- Comprehensive Interventional Care Centers (CICC) - Gilbert
- The Institute for Liver Health - Glendale
- The Institute for Liver Health - Peoria
- Comprehensive Interventional Care Centers (CICC) - Sun City
- Institute for Liver Health DBA Arizona Liver Health - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04321031
The ClinicalTrials.gov registry entry for NCT04321031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 9 other Nonalcoholic Fatty Liver Disease trials with a reported enrollment target (194% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Nonalcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04321031 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04321031 about?
NCT04321031 is a clinical study titled "Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)". The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on ...
What is the current status of trial NCT04321031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2020-06-15. Estimated completion is 2024-02-21.
What conditions does trial NCT04321031 study?
This clinical trial studies the following conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis.
What interventions are being tested in trial NCT04321031?
The interventions under investigation include: Placebo (DRUG), PF-06865571 (DRUG), PF-05221304 (DRUG).
Who is sponsoring clinical trial NCT04321031?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04321031 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2b Study of GSK4532990 in Adults With NASH
ACTIVE NOT RECRUITING · Phase 2
-
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
COMPLETED · Phase 2
-
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
COMPLETED · Phase 2
-
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
RECRUITING
-
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
ACTIVE NOT RECRUITING
-
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
COMPLETED · Phase 3
Explore more on PlainTrial
Nonalcoholic Fatty Liver Disease
All registered trials for this condition
Nonalcoholic Steatohepatitis With Liver Fibrosis
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.